Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,843.84 -33.21 (-0.42%) Bitcoin USD
65,310.12 +3,053.06 (+4.90%) CMC Crypto 200
1,343.86 +31.23 (+2.44%)
Verve Therapeutics, Inc. (VERV)
Pre-market:
| Previous close | 6.74 |
| Open | 6.70 |
| Bid | 6.64 x 600 |
| Ask | 6.68 x 600 |
| Day's range | 6.53 - 6.85 |
| 52-week range | 6.53 - 21.42 |
| Volume | |
| Avg. volume | 1,290,495 |
| Market cap | 556.905M |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.12 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.13 |
ZacksBiotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
ZacksVerve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.
- Reuters
UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
Verve Therapeutics said on Tuesday that it had paused enrollment for an early-stage study testing its experimental gene editing therapy for high cholesterol after a patient experienced a severe drug-related adverse event. The company was testing the therapy in patients with a genetic condition that leads to high cholesterol levels, which raises the risk of heart disease. The treatment is supposed to permanently turn off a protein called PCSK9 helping reduce blood cholesterol levels.
